贝伐珠单抗在非小细胞肺癌中应用的研究现状被引量：12

Current Indication of Bevacizumab Treatment for Non-Small Cell Lung Cancer

导出

摘要目前非小细胞肺癌化疗疗效已经达平台期,亟需寻找新的方法提高疗效。贝伐珠单抗是一种重组抗VEGF单克隆抗体,是首个证实与化疗联合可提高晚期NSCLC患者生存的靶向治疗药物。近年来许多关于贝伐珠单抗在NSCLC一线、二线、辅助、新辅助治疗、联合放化疗,安全性及预测标志物的临床研究,现将其研究现状做一综述。 At present, chemotherapy for non-small cell lung cancer （NSCLC） has reached a therapeutic plateau; new treatment options are needed to improve efficacy. Bevacizumab is a vascular endothelial growth factor monoclonal antibody. It is the first targeted therapy confirmed to improve the chemotherapy survival in advanced NSCLC. Many clinical studies about bevacizumab as first-line, second-line, adjuvant, and neoadjuvant treatments with chemoradiation are ongoing. The article reviews the current indications for bevacizumab.

作者陈筱玲方健

机构地区北京大学临床肿瘤学院北京肿瘤医院暨北京市肿瘤防治研究所

出处《中国肿瘤临床》 CAS CSCD 北大核心 2011年第12期747-750,共4页 Chinese Journal of Clinical Oncology

关键词贝伐珠单抗非小细胞肺癌有效性安全性预测因子 Bevacizumab, NSCLC, Efficacy, Safety, Predictive marker

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献19

1Johnson DH,Fehrenbacher L,Novotny WF,et al.Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol,2004,22(11):2184-2191.
2Sandler A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,355(24):2542-2550.
3Ramalingam SS,Dahlberg SE,Langer CJ,et al.Outcomes for elderly,advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel:analysis of Eastern Cooperative Oncology Group Trial 4599[J].J Clin Oncol,2008,26(1):60-65.
4Reck M,von Pawel J,Zatloukal P,et al.Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer:AVAil[J].J Clin Oncol,2009,27(8):1227-1234.
5Patel JD,Bonomi P,Socinski MA,et al.Treatment rationale and study design for the pointbreak study:a randomized,open-label phase Ⅲstudy of pemetrexed/carboplatin/bevacizumab followed by maintenance pemerexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage ⅢB or Ⅳ nonsquamous non-small-cell lung cancer[J].Clin Lung Cancer,2009,10(4):252-256.
6Crinò L,Dansin E,Garrido P,et al.Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL,MO19390):a phase 4 study[J].LancetOncol,2010,11(8):733-740.
7Herbst RS,O'Neill VJ,Fehrenbacher L,et al.Phase Ⅱ study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer[J].J Clin Oncol,2007,25(30):4743-4750.
8Herbst RS,Stern H,Amler L,et al.Biomarker evaluation in the Phase Ⅲ,placebo (P)-controlled,randomized BeTa trial of bevacizumab(B) and erlotinib(E) for patients(pts) with advanced non-small cell lung cancer(NSCLC) after failure of standard 1st-line chemotherapy:correlation with treatment outcomes[J].2009 AACR Annual Meeting April 18-22.
9Price K,Kris MG,Rusch V,et al.Phase Ⅱ study of induction and adjuvant bevacizumab in patients with stage ⅠB-ⅢA non-small cell lung cancer (NSCLC) receiving induction docetaxel and cisplat in[J].J Clin Oncol,2009,27(Suppl):15s,abstr 7531.
10Spigel DR,Hainsworth JD,Yardley DA,et al.Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab[J].J Clin Oncol,2010,28(1):43-48.